| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 81 | 2024 | 656 | 17.990 |
Why?
|
| Barrett Esophagus | 63 | 2021 | 114 | 15.380 |
Why?
|
| Esophageal Neoplasms | 69 | 2021 | 116 | 13.240 |
Why?
|
| Adenocarcinoma | 69 | 2022 | 177 | 13.220 |
Why?
|
| Early Detection of Cancer | 68 | 2024 | 526 | 11.390 |
Why?
|
| Adenoma | 22 | 2024 | 100 | 9.880 |
Why?
|
| Colonoscopy | 47 | 2024 | 268 | 9.860 |
Why?
|
| Humans | 266 | 2024 | 18430 | 5.440 |
Why?
|
| Gastroesophageal Reflux | 31 | 2021 | 79 | 5.270 |
Why?
|
| Gastroenterology | 11 | 2022 | 19 | 5.150 |
Why?
|
| Occult Blood | 22 | 2024 | 167 | 4.590 |
Why?
|
| Male | 162 | 2024 | 10440 | 4.320 |
Why?
|
| Proton Pump Inhibitors | 10 | 2020 | 25 | 4.270 |
Why?
|
| Aged | 130 | 2024 | 6417 | 4.210 |
Why?
|
| Stomach Neoplasms | 15 | 2020 | 42 | 4.200 |
Why?
|
| Middle Aged | 142 | 2024 | 8284 | 4.160 |
Why?
|
| Female | 175 | 2024 | 13136 | 3.900 |
Why?
|
| Risk Factors | 92 | 2023 | 3449 | 3.630 |
Why?
|
| Precancerous Conditions | 14 | 2020 | 48 | 3.400 |
Why?
|
| Mass Screening | 32 | 2024 | 690 | 3.210 |
Why?
|
| Case-Control Studies | 56 | 2024 | 1173 | 3.070 |
Why?
|
| California | 51 | 2024 | 2365 | 2.700 |
Why?
|
| Aged, 80 and over | 50 | 2024 | 2003 | 2.280 |
Why?
|
| Adult | 79 | 2024 | 7910 | 2.270 |
Why?
|
| Aspirin | 7 | 2019 | 67 | 2.230 |
Why?
|
| Feces | 10 | 2024 | 88 | 2.210 |
Why?
|
| Genetic Predisposition to Disease | 23 | 2024 | 414 | 2.040 |
Why?
|
| Quality Improvement | 4 | 2024 | 207 | 2.020 |
Why?
|
| Time Factors | 32 | 2021 | 1136 | 1.960 |
Why?
|
| Risk Assessment | 33 | 2024 | 1143 | 1.890 |
Why?
|
| Histamine H2 Antagonists | 4 | 2016 | 13 | 1.840 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2024 | 16 | 1.820 |
Why?
|
| Incidence | 37 | 2022 | 1314 | 1.790 |
Why?
|
| Retrospective Studies | 37 | 2024 | 2550 | 1.790 |
Why?
|
| Colonic Polyps | 4 | 2023 | 35 | 1.720 |
Why?
|
| Practice Guidelines as Topic | 8 | 2024 | 333 | 1.670 |
Why?
|
| Odds Ratio | 24 | 2018 | 701 | 1.670 |
Why?
|
| Chemical and Drug Induced Liver Injury | 4 | 2015 | 10 | 1.660 |
Why?
|
| Polymorphism, Single Nucleotide | 24 | 2023 | 412 | 1.550 |
Why?
|
| Esophagus | 9 | 2015 | 12 | 1.510 |
Why?
|
| Obesity | 20 | 2020 | 855 | 1.510 |
Why?
|
| Body Mass Index | 18 | 2017 | 974 | 1.510 |
Why?
|
| Liver Neoplasms | 4 | 2020 | 42 | 1.480 |
Why?
|
| Diet | 7 | 2015 | 371 | 1.460 |
Why?
|
| Neoplasms | 10 | 2022 | 457 | 1.440 |
Why?
|
| Age Factors | 23 | 2024 | 965 | 1.430 |
Why?
|
| Uterine Cervical Neoplasms | 7 | 2022 | 127 | 1.420 |
Why?
|
| Cardia | 7 | 2008 | 15 | 1.410 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2016 | 68 | 1.400 |
Why?
|
| Periodicals as Topic | 3 | 2021 | 14 | 1.340 |
Why?
|
| Esophagoscopy | 10 | 2015 | 19 | 1.310 |
Why?
|
| Liver Failure, Acute | 4 | 2015 | 4 | 1.280 |
Why?
|
| Biomarkers, Tumor | 7 | 2021 | 146 | 1.240 |
Why?
|
| Young Adult | 26 | 2024 | 2518 | 1.230 |
Why?
|
| Gastroenterologists | 3 | 2017 | 7 | 1.230 |
Why?
|
| Genome-Wide Association Study | 24 | 2023 | 252 | 1.220 |
Why?
|
| Telemedicine | 2 | 2020 | 184 | 1.140 |
Why?
|
| Physicians | 3 | 2022 | 141 | 1.140 |
Why?
|
| Logistic Models | 19 | 2021 | 962 | 1.110 |
Why?
|
| Databases, Factual | 12 | 2019 | 327 | 1.110 |
Why?
|
| Decision Support Techniques | 3 | 2017 | 95 | 1.090 |
Why?
|
| Sex Factors | 18 | 2020 | 661 | 1.070 |
Why?
|
| Predictive Value of Tests | 11 | 2021 | 365 | 1.070 |
Why?
|
| United States | 38 | 2022 | 4164 | 1.060 |
Why?
|
| Smoking | 12 | 2019 | 494 | 1.040 |
Why?
|
| Cohort Studies | 23 | 2024 | 2672 | 1.000 |
Why?
|
| Helicobacter pylori | 6 | 2017 | 24 | 0.980 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2015 | 55 | 0.970 |
Why?
|
| Iron | 3 | 2016 | 17 | 0.970 |
Why?
|
| Catheter Ablation | 3 | 2013 | 11 | 0.960 |
Why?
|
| Alcohol Drinking | 7 | 2015 | 375 | 0.960 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2014 | 22 | 0.960 |
Why?
|
| Healthcare Disparities | 9 | 2022 | 211 | 0.950 |
Why?
|
| Hepatitis B Vaccines | 2 | 2014 | 46 | 0.940 |
Why?
|
| Vitamin B 12 Deficiency | 2 | 2014 | 3 | 0.940 |
Why?
|
| Hepatitis B | 2 | 2014 | 43 | 0.930 |
Why?
|
| Sigmoidoscopy | 7 | 2020 | 67 | 0.930 |
Why?
|
| Aftercare | 4 | 2020 | 48 | 0.920 |
Why?
|
| Surveys and Questionnaires | 15 | 2024 | 1389 | 0.910 |
Why?
|
| African Americans | 7 | 2022 | 490 | 0.910 |
Why?
|
| Genetic Testing | 1 | 2024 | 89 | 0.910 |
Why?
|
| Diphosphonates | 8 | 2020 | 62 | 0.890 |
Why?
|
| Immunologic Tests | 2 | 2020 | 6 | 0.870 |
Why?
|
| Biomedical Research | 3 | 2021 | 93 | 0.860 |
Why?
|
| Sensitivity and Specificity | 12 | 2022 | 321 | 0.860 |
Why?
|
| Helicobacter Infections | 5 | 2017 | 22 | 0.850 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2022 | 407 | 0.850 |
Why?
|
| Pandemics | 4 | 2022 | 292 | 0.830 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2019 | 8 | 0.810 |
Why?
|
| Cardiovascular Diseases | 4 | 2022 | 630 | 0.810 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2020 | 26 | 0.810 |
Why?
|
| Adolescent | 22 | 2024 | 3798 | 0.810 |
Why?
|
| Breast Neoplasms | 7 | 2020 | 1037 | 0.800 |
Why?
|
| Gastrointestinal Diseases | 3 | 2015 | 28 | 0.790 |
Why?
|
| Femoral Fractures | 5 | 2020 | 22 | 0.790 |
Why?
|
| SEER Program | 7 | 2021 | 101 | 0.790 |
Why?
|
| Cross-Sectional Studies | 12 | 2024 | 1360 | 0.770 |
Why?
|
| Evidence-Based Medicine | 2 | 2019 | 195 | 0.760 |
Why?
|
| Publishing | 1 | 2021 | 9 | 0.760 |
Why?
|
| Algorithms | 5 | 2020 | 241 | 0.750 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2020 | 4 | 0.730 |
Why?
|
| Azithromycin | 1 | 2020 | 3 | 0.730 |
Why?
|
| Infection Control | 1 | 2020 | 10 | 0.720 |
Why?
|
| Health Planning | 1 | 2020 | 17 | 0.720 |
Why?
|
| Bone Density Conservation Agents | 6 | 2020 | 55 | 0.720 |
Why?
|
| Colonic Neoplasms | 4 | 2017 | 157 | 0.720 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2019 | 10 | 0.720 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 13 | 0.720 |
Why?
|
| Laboratories | 1 | 2020 | 23 | 0.720 |
Why?
|
| Kidney Neoplasms | 5 | 2019 | 16 | 0.710 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 19 | 0.710 |
Why?
|
| Population Surveillance | 7 | 2019 | 271 | 0.710 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 43 | 0.700 |
Why?
|
| Research Personnel | 1 | 2020 | 30 | 0.700 |
Why?
|
| Pancreatic Neoplasms | 2 | 2020 | 69 | 0.700 |
Why?
|
| Gastrointestinal Tract | 3 | 2022 | 7 | 0.690 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.690 |
Why?
|
| Fatigue | 2 | 2016 | 35 | 0.680 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 232 | 0.670 |
Why?
|
| Transaminases | 2 | 2015 | 2 | 0.660 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.660 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.660 |
Why?
|
| Health Personnel | 1 | 2020 | 126 | 0.650 |
Why?
|
| Continental Population Groups | 7 | 2017 | 315 | 0.640 |
Why?
|
| Societies, Medical | 2 | 2017 | 74 | 0.640 |
Why?
|
| Health Services Research | 2 | 2014 | 264 | 0.640 |
Why?
|
| Antioxidants | 3 | 2015 | 40 | 0.630 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 142 | 0.630 |
Why?
|
| Quality Indicators, Health Care | 2 | 2022 | 197 | 0.630 |
Why?
|
| Patient Participation | 1 | 2019 | 144 | 0.630 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2015 | 9 | 0.620 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2014 | 20 | 0.620 |
Why?
|
| Electronic Health Records | 6 | 2024 | 747 | 0.600 |
Why?
|
| Heartburn | 2 | 2014 | 4 | 0.590 |
Why?
|
| International Classification of Diseases | 2 | 2015 | 87 | 0.560 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 54 | 0.560 |
Why?
|
| Standard of Care | 1 | 2016 | 7 | 0.550 |
Why?
|
| Ethnic Groups | 8 | 2017 | 501 | 0.550 |
Why?
|
| Patient Compliance | 3 | 2016 | 318 | 0.550 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 399 | 0.540 |
Why?
|
| Ghrelin | 2 | 2015 | 15 | 0.540 |
Why?
|
| Colon | 4 | 2020 | 21 | 0.540 |
Why?
|
| Papillomaviridae | 2 | 2022 | 53 | 0.540 |
Why?
|
| Endoscopy | 2 | 2014 | 10 | 0.530 |
Why?
|
| Triazoles | 1 | 2015 | 2 | 0.530 |
Why?
|
| Esophagogastric Junction | 6 | 2021 | 6 | 0.530 |
Why?
|
| Ablation Techniques | 2 | 2015 | 3 | 0.530 |
Why?
|
| Antifungal Agents | 1 | 2015 | 4 | 0.530 |
Why?
|
| Ambulatory Care | 2 | 2017 | 266 | 0.530 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 21 | 0.530 |
Why?
|
| Obesity, Abdominal | 1 | 2015 | 11 | 0.520 |
Why?
|
| Registries | 7 | 2021 | 490 | 0.520 |
Why?
|
| Nurses | 1 | 2015 | 40 | 0.520 |
Why?
|
| Leptin | 1 | 2015 | 30 | 0.520 |
Why?
|
| Patient-Centered Care | 2 | 2015 | 228 | 0.510 |
Why?
|
| Immune System | 1 | 2015 | 2 | 0.510 |
Why?
|
| Food Hypersensitivity | 1 | 2015 | 5 | 0.510 |
Why?
|
| Data Collection | 2 | 2019 | 275 | 0.510 |
Why?
|
| Clinical Coding | 1 | 2015 | 11 | 0.510 |
Why?
|
| Process Assessment (Health Care) | 1 | 2015 | 28 | 0.500 |
Why?
|
| Immunochemistry | 2 | 2017 | 19 | 0.500 |
Why?
|
| Colonic Diseases | 1 | 2015 | 3 | 0.500 |
Why?
|
| Quality of Health Care | 2 | 2022 | 347 | 0.500 |
Why?
|
| Adiponectin | 1 | 2015 | 22 | 0.490 |
Why?
|
| Health Care Costs | 3 | 2016 | 251 | 0.490 |
Why?
|
| DNA, Neoplasm | 1 | 2014 | 21 | 0.480 |
Why?
|
| Feeding Behavior | 2 | 2015 | 168 | 0.470 |
Why?
|
| Dietary Fiber | 3 | 2013 | 60 | 0.450 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 1269 | 0.450 |
Why?
|
| Germ-Line Mutation | 5 | 2021 | 23 | 0.450 |
Why?
|
| Primary Health Care | 2 | 2017 | 848 | 0.450 |
Why?
|
| Protective Factors | 4 | 2018 | 33 | 0.450 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 17 | 0.440 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 259 | 0.440 |
Why?
|
| Waist Circumference | 1 | 2013 | 38 | 0.430 |
Why?
|
| Hip Fractures | 3 | 2014 | 68 | 0.420 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2013 | 20 | 0.410 |
Why?
|
| Survival Rate | 5 | 2021 | 269 | 0.410 |
Why?
|
| Prognosis | 7 | 2020 | 624 | 0.400 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2013 | 19 | 0.400 |
Why?
|
| Risk | 9 | 2016 | 552 | 0.400 |
Why?
|
| Bias | 5 | 2022 | 111 | 0.400 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 4 | 0.390 |
Why?
|
| European Continental Ancestry Group | 8 | 2020 | 554 | 0.390 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 598 | 0.380 |
Why?
|
| Fruit | 3 | 2015 | 79 | 0.370 |
Why?
|
| Vegetables | 3 | 2015 | 87 | 0.360 |
Why?
|
| Postoperative Complications | 2 | 2022 | 103 | 0.360 |
Why?
|
| Meat | 2 | 2015 | 27 | 0.360 |
Why?
|
| Models, Statistical | 5 | 2017 | 185 | 0.350 |
Why?
|
| DNA Mismatch Repair | 2 | 2020 | 5 | 0.350 |
Why?
|
| Gene-Environment Interaction | 3 | 2017 | 20 | 0.350 |
Why?
|
| Proportional Hazards Models | 5 | 2019 | 743 | 0.350 |
Why?
|
| Chemoprevention | 1 | 2009 | 12 | 0.350 |
Why?
|
| Bone Density | 3 | 2016 | 96 | 0.340 |
Why?
|
| Peer Review, Research | 2 | 2021 | 3 | 0.340 |
Why?
|
| Anticarcinogenic Agents | 3 | 2015 | 14 | 0.340 |
Why?
|
| Outcome Assessment (Health Care) | 3 | 2016 | 254 | 0.330 |
Why?
|
| Mutation | 2 | 2017 | 132 | 0.330 |
Why?
|
| Osteoporosis, Postmenopausal | 2 | 2011 | 44 | 0.330 |
Why?
|
| Beer | 1 | 2008 | 9 | 0.330 |
Why?
|
| Disease Progression | 6 | 2017 | 271 | 0.320 |
Why?
|
| Ferritins | 1 | 2008 | 10 | 0.320 |
Why?
|
| Wine | 1 | 2008 | 18 | 0.320 |
Why?
|
| Prevalence | 8 | 2019 | 911 | 0.320 |
Why?
|
| Dietary Fats | 1 | 2009 | 92 | 0.320 |
Why?
|
| Hemochromatosis | 1 | 2008 | 9 | 0.320 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 8 | 0.320 |
Why?
|
| Osteoporosis | 2 | 2016 | 76 | 0.310 |
Why?
|
| Membrane Proteins | 1 | 2008 | 40 | 0.310 |
Why?
|
| Hemoglobins | 2 | 2019 | 39 | 0.310 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 136 | 0.300 |
Why?
|
| Cancer Survivors | 2 | 2020 | 89 | 0.300 |
Why?
|
| Genetic Variation | 2 | 2016 | 87 | 0.300 |
Why?
|
| HIV Infections | 3 | 2019 | 695 | 0.290 |
Why?
|
| Abdominal Fat | 1 | 2007 | 15 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 131 | 0.290 |
Why?
|
| Disease Management | 3 | 2019 | 143 | 0.290 |
Why?
|
| Health Status Disparities | 4 | 2022 | 153 | 0.280 |
Why?
|
| Comorbidity | 6 | 2019 | 619 | 0.280 |
Why?
|
| Age of Onset | 3 | 2021 | 82 | 0.280 |
Why?
|
| Liver Diseases | 2 | 2015 | 25 | 0.280 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2006 | 3 | 0.270 |
Why?
|
| Prostatic Neoplasms | 2 | 2022 | 298 | 0.270 |
Why?
|
| Esomeprazole | 2 | 2019 | 2 | 0.270 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 159 | 0.270 |
Why?
|
| Administration, Oral | 5 | 2017 | 86 | 0.270 |
Why?
|
| Workload | 2 | 2016 | 30 | 0.260 |
Why?
|
| Diabetes Mellitus | 4 | 2019 | 530 | 0.260 |
Why?
|
| Medical History Taking | 3 | 2020 | 37 | 0.260 |
Why?
|
| Animals | 4 | 2015 | 261 | 0.260 |
Why?
|
| Models, Genetic | 3 | 2017 | 24 | 0.250 |
Why?
|
| Pregnancy Complications | 1 | 2007 | 193 | 0.250 |
Why?
|
| Clinical Competence | 3 | 2015 | 108 | 0.240 |
Why?
|
| Genetic Loci | 5 | 2020 | 60 | 0.240 |
Why?
|
| Diffusion of Innovation | 1 | 2024 | 44 | 0.240 |
Why?
|
| Leadership | 1 | 2024 | 45 | 0.240 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 4 | 0.240 |
Why?
|
| Evidence-Based Practice | 1 | 2024 | 56 | 0.240 |
Why?
|
| Prospective Studies | 5 | 2020 | 1314 | 0.240 |
Why?
|
| Rectal Neoplasms | 2 | 2016 | 67 | 0.230 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 65 | 0.230 |
Why?
|
| Radio Waves | 1 | 2003 | 2 | 0.230 |
Why?
|
| Molecular Epidemiology | 2 | 2021 | 44 | 0.230 |
Why?
|
| Pregnancy | 4 | 2014 | 1516 | 0.230 |
Why?
|
| Hypertension | 5 | 2019 | 524 | 0.220 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2015 | 567 | 0.220 |
Why?
|
| HIV Enteropathy | 2 | 2000 | 2 | 0.220 |
Why?
|
| Neoplasm Staging | 4 | 2017 | 337 | 0.220 |
Why?
|
| Education, Medical, Continuing | 2 | 2017 | 31 | 0.220 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2015 | 180 | 0.220 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2022 | 15 | 0.210 |
Why?
|
| Benchmarking | 1 | 2022 | 45 | 0.210 |
Why?
|
| Hispanic Americans | 4 | 2017 | 428 | 0.200 |
Why?
|
| Confidence Intervals | 4 | 2013 | 253 | 0.200 |
Why?
|
| Biopsy | 5 | 2018 | 75 | 0.200 |
Why?
|
| Patient Selection | 1 | 2003 | 198 | 0.200 |
Why?
|
| Pilot Projects | 2 | 2020 | 237 | 0.200 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2006 | 19 | 0.200 |
Why?
|
| Artifacts | 1 | 2021 | 3 | 0.200 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2012 | 350 | 0.200 |
Why?
|
| Prejudice | 1 | 2021 | 24 | 0.200 |
Why?
|
| Cultural Diversity | 1 | 2021 | 17 | 0.200 |
Why?
|
| Consensus | 3 | 2018 | 41 | 0.200 |
Why?
|
| Perimenopause | 1 | 2011 | 11 | 0.200 |
Why?
|
| Mouth Diseases | 1 | 2011 | 3 | 0.190 |
Why?
|
| Somatomedins | 1 | 2021 | 5 | 0.190 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2020 | 19 | 0.190 |
Why?
|
| Lypressin | 1 | 2001 | 1 | 0.190 |
Why?
|
| Octreotide | 1 | 2001 | 1 | 0.190 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2001 | 4 | 0.190 |
Why?
|
| Hemostatics | 1 | 2001 | 3 | 0.190 |
Why?
|
| Oral Health | 1 | 2011 | 21 | 0.190 |
Why?
|
| Cause of Death | 2 | 2019 | 185 | 0.190 |
Why?
|
| Hemorrhage | 1 | 2001 | 63 | 0.190 |
Why?
|
| Mammography | 3 | 2017 | 174 | 0.190 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 45 | 0.190 |
Why?
|
| Carcinogenesis | 1 | 2020 | 9 | 0.180 |
Why?
|
| Choice Behavior | 1 | 2020 | 48 | 0.180 |
Why?
|
| Genome, Human | 1 | 2020 | 42 | 0.180 |
Why?
|
| Metaplasia | 2 | 2011 | 7 | 0.180 |
Why?
|
| Global Burden of Disease | 1 | 2020 | 1 | 0.180 |
Why?
|
| Radiography, Thoracic | 1 | 2020 | 19 | 0.180 |
Why?
|
| Survival Analysis | 4 | 2017 | 226 | 0.180 |
Why?
|
| Congresses as Topic | 1 | 2020 | 13 | 0.180 |
Why?
|
| Microsatellite Instability | 1 | 2020 | 16 | 0.180 |
Why?
|
| Demography | 1 | 2020 | 108 | 0.180 |
Why?
|
| Medical Marijuana | 1 | 2020 | 24 | 0.170 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 7 | 0.170 |
Why?
|
| Fractures, Spontaneous | 1 | 2019 | 3 | 0.170 |
Why?
|
| Lung Diseases | 2 | 1997 | 43 | 0.170 |
Why?
|
| Proton Pumps | 1 | 2019 | 1 | 0.170 |
Why?
|
| Reference Standards | 1 | 2019 | 17 | 0.170 |
Why?
|
| Rivaroxaban | 1 | 2019 | 7 | 0.170 |
Why?
|
| Laparoscopy | 1 | 2019 | 48 | 0.170 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 46 | 0.170 |
Why?
|
| Life Style | 4 | 2019 | 342 | 0.170 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 320 | 0.170 |
Why?
|
| Australia | 3 | 2017 | 23 | 0.170 |
Why?
|
| Natural Language Processing | 1 | 2020 | 57 | 0.160 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 157 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 208 | 0.160 |
Why?
|
| Asian Continental Ancestry Group | 3 | 2020 | 90 | 0.160 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 100 | 0.160 |
Why?
|
| Information Dissemination | 2 | 2016 | 57 | 0.160 |
Why?
|
| Tumor Burden | 1 | 2018 | 20 | 0.160 |
Why?
|
| Asian Americans | 4 | 2016 | 182 | 0.160 |
Why?
|
| Medical Overuse | 1 | 2018 | 13 | 0.160 |
Why?
|
| Alendronate | 2 | 2009 | 15 | 0.160 |
Why?
|
| Guideline Adherence | 2 | 2016 | 162 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 36 | 0.160 |
Why?
|
| Infant, Newborn | 2 | 2014 | 872 | 0.160 |
Why?
|
| Stomach Diseases | 1 | 1998 | 1 | 0.160 |
Why?
|
| Confounding Factors (Epidemiology) | 2 | 2008 | 99 | 0.150 |
Why?
|
| Tea | 2 | 2015 | 8 | 0.150 |
Why?
|
| Anniversaries and Special Events | 1 | 2017 | 1 | 0.150 |
Why?
|
| Mucormycosis | 1 | 1997 | 1 | 0.150 |
Why?
|
| Stomach Ulcer | 1 | 1997 | 3 | 0.150 |
Why?
|
| History, 20th Century | 1 | 2017 | 10 | 0.150 |
Why?
|
| Delphi Technique | 2 | 2015 | 33 | 0.150 |
Why?
|
| Heart Transplantation | 1 | 1997 | 11 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2017 | 25 | 0.150 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2014 | 24 | 0.150 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 1997 | 1 | 0.150 |
Why?
|
| Dietary Carbohydrates | 1 | 2017 | 27 | 0.150 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1997 | 4 | 0.150 |
Why?
|
| Dietary Sugars | 1 | 2017 | 6 | 0.150 |
Why?
|
| Hypoxia | 1 | 1997 | 8 | 0.150 |
Why?
|
| Pathologists | 1 | 2017 | 15 | 0.150 |
Why?
|
| Patient Navigation | 1 | 2017 | 17 | 0.150 |
Why?
|
| Intestinal Polyps | 1 | 2017 | 7 | 0.150 |
Why?
|
| Abdomen | 2 | 2008 | 21 | 0.150 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 1997 | 1 | 0.150 |
Why?
|
| Gastric Outlet Obstruction | 1 | 1997 | 1 | 0.150 |
Why?
|
| Osteoporotic Fractures | 2 | 2016 | 40 | 0.150 |
Why?
|
| Biomarkers | 2 | 2015 | 308 | 0.140 |
Why?
|
| Digestive System Diseases | 1 | 2017 | 3 | 0.140 |
Why?
|
| Lung | 1 | 1997 | 62 | 0.140 |
Why?
|
| Bone Morphogenetic Protein 3 | 1 | 2017 | 3 | 0.140 |
Why?
|
| Muscle Proteins | 1 | 2017 | 5 | 0.140 |
Why?
|
| Genes, ras | 1 | 2017 | 5 | 0.140 |
Why?
|
| Malabsorption Syndromes | 1 | 2016 | 1 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 112 | 0.140 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 24 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 21 | 0.140 |
Why?
|
| Health Maintenance Organizations | 2 | 2013 | 479 | 0.140 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 25 | 0.140 |
Why?
|
| Multifactorial Inheritance | 3 | 2023 | 20 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2016 | 22 | 0.140 |
Why?
|
| Glutathione Transferase | 1 | 2016 | 13 | 0.140 |
Why?
|
| Population Health | 1 | 2016 | 5 | 0.140 |
Why?
|
| Leukocytes | 1 | 2016 | 9 | 0.140 |
Why?
|
| Regression Analysis | 1 | 2017 | 319 | 0.140 |
Why?
|
| Journal Impact Factor | 1 | 2016 | 2 | 0.140 |
Why?
|
| Authorship | 1 | 2016 | 5 | 0.140 |
Why?
|
| Editorial Policies | 1 | 2016 | 5 | 0.140 |
Why?
|
| Telomere | 1 | 2016 | 19 | 0.140 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 34 | 0.140 |
Why?
|
| Safety-net Providers | 1 | 2017 | 63 | 0.140 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 1 | 2016 | 33 | 0.140 |
Why?
|
| Access to Information | 1 | 2016 | 13 | 0.140 |
Why?
|
| Government Regulation | 1 | 2016 | 8 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2016 | 22 | 0.140 |
Why?
|
| Fractures, Bone | 2 | 2011 | 91 | 0.130 |
Why?
|
| Jaw Diseases | 2 | 2011 | 9 | 0.130 |
Why?
|
| Goals | 1 | 2016 | 33 | 0.130 |
Why?
|
| Osteonecrosis | 2 | 2011 | 10 | 0.130 |
Why?
|
| Immunoassay | 1 | 2016 | 9 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2015 | 760 | 0.130 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2015 | 2 | 0.130 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2015 | 1 | 0.130 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2015 | 2 | 0.130 |
Why?
|
| Receptors, Oxytocin | 1 | 2015 | 1 | 0.130 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2019 | 33 | 0.130 |
Why?
|
| Psychological Theory | 1 | 2015 | 3 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 6 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2015 | 13 | 0.130 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2015 | 16 | 0.130 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2015 | 3 | 0.130 |
Why?
|
| Lactic Acid | 1 | 2005 | 9 | 0.130 |
Why?
|
| Animal Feed | 1 | 2015 | 1 | 0.130 |
Why?
|
| Food Preservation | 1 | 2015 | 1 | 0.130 |
Why?
|
| Calicivirus, Feline | 1 | 2015 | 1 | 0.130 |
Why?
|
| Attention | 1 | 2015 | 10 | 0.130 |
Why?
|
| Community Health Services | 1 | 2016 | 86 | 0.130 |
Why?
|
| Fasting | 1 | 2005 | 48 | 0.130 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 27 | 0.130 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2005 | 21 | 0.130 |
Why?
|
| Platelet Count | 1 | 2015 | 9 | 0.130 |
Why?
|
| Observation | 1 | 2015 | 25 | 0.130 |
Why?
|
| Survivors | 1 | 2017 | 158 | 0.130 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 12 | 0.130 |
Why?
|
| Bilirubin | 1 | 2015 | 30 | 0.130 |
Why?
|
| Liver Function Tests | 1 | 2015 | 6 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 22 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2015 | 17 | 0.130 |
Why?
|
| Pharmacoepidemiology | 1 | 2015 | 22 | 0.130 |
Why?
|
| Microbiota | 1 | 2015 | 7 | 0.130 |
Why?
|
| Nutritional Status | 1 | 2015 | 30 | 0.130 |
Why?
|
| Focus Groups | 1 | 2015 | 154 | 0.120 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2014 | 1 | 0.120 |
Why?
|
| Social Environment | 1 | 2015 | 90 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2016 | 244 | 0.120 |
Why?
|
| Metformin | 1 | 2015 | 61 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 16 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2015 | 47 | 0.120 |
Why?
|
| Growth Differentiation Factors | 1 | 2014 | 1 | 0.120 |
Why?
|
| T-Box Domain Proteins | 1 | 2014 | 4 | 0.120 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2014 | 3 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2014 | 21 | 0.120 |
Why?
|
| Papillomavirus Vaccines | 1 | 2016 | 118 | 0.120 |
Why?
|
| Community-Institutional Relations | 1 | 2015 | 47 | 0.120 |
Why?
|
| Liver Cirrhosis | 2 | 2020 | 34 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2014 | 4 | 0.120 |
Why?
|
| Medicare | 1 | 2016 | 214 | 0.120 |
Why?
|
| Health Policy | 1 | 2016 | 136 | 0.120 |
Why?
|
| Cytoprotection | 1 | 2014 | 1 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2005 | 129 | 0.120 |
Why?
|
| Citrus | 1 | 2014 | 3 | 0.120 |
Why?
|
| Lycopersicon esculentum | 1 | 2014 | 4 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 102 | 0.120 |
Why?
|
| Diet, High-Fat | 1 | 2014 | 6 | 0.120 |
Why?
|
| Medicaid | 1 | 2016 | 211 | 0.120 |
Why?
|
| Carbonated Beverages | 1 | 2014 | 14 | 0.120 |
Why?
|
| Diet, Fat-Restricted | 1 | 2014 | 38 | 0.120 |
Why?
|
| Alcoholic Beverages | 1 | 2014 | 14 | 0.120 |
Why?
|
| Motivation | 1 | 2015 | 137 | 0.120 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 12 | 0.120 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 21 | 0.120 |
Why?
|
| Interviews as Topic | 2 | 2011 | 327 | 0.120 |
Why?
|
| Perinatal Care | 1 | 2014 | 13 | 0.120 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2015 | 110 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 114 | 0.120 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 18 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2015 | 127 | 0.120 |
Why?
|
| Community Networks | 1 | 2014 | 28 | 0.120 |
Why?
|
| Overweight | 2 | 2015 | 276 | 0.120 |
Why?
|
| Chromosome Disorders | 1 | 2013 | 3 | 0.120 |
Why?
|
| Body Height | 1 | 2014 | 62 | 0.110 |
Why?
|
| Viral Load | 1 | 2014 | 135 | 0.110 |
Why?
|
| Principal Component Analysis | 2 | 2016 | 23 | 0.110 |
Why?
|
| Homozygote | 2 | 2015 | 14 | 0.110 |
Why?
|
| Health Promotion | 1 | 2016 | 294 | 0.110 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 444 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2012 | 2 | 0.110 |
Why?
|
| Prehypertension | 1 | 2013 | 22 | 0.110 |
Why?
|
| Major Histocompatibility Complex | 1 | 2012 | 3 | 0.110 |
Why?
|
| Pulmonary Embolism | 1 | 2013 | 44 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 288 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2015 | 1296 | 0.110 |
Why?
|
| Dinoprostone | 1 | 2012 | 2 | 0.110 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2012 | 2 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2015 | 468 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 476 | 0.100 |
Why?
|
| Esophagectomy | 1 | 2012 | 2 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2012 | 7 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 52 | 0.100 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2012 | 1 | 0.100 |
Why?
|
| Bile Ducts | 1 | 2012 | 3 | 0.100 |
Why?
|
| Intraoperative Complications | 1 | 2012 | 5 | 0.100 |
Why?
|
| Polyps | 1 | 1992 | 1 | 0.100 |
Why?
|
| Uterine Hemorrhage | 1 | 1992 | 9 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 58 | 0.100 |
Why?
|
| Endometrial Neoplasms | 1 | 1992 | 39 | 0.100 |
Why?
|
| Intestines | 1 | 2011 | 4 | 0.100 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 673 | 0.100 |
Why?
|
| Tamoxifen | 1 | 1992 | 60 | 0.100 |
Why?
|
| Feedback | 1 | 2011 | 22 | 0.100 |
Why?
|
| Micronutrients | 1 | 2010 | 9 | 0.090 |
Why?
|
| Computer Simulation | 2 | 2024 | 85 | 0.090 |
Why?
|
| Gastric Acid | 1 | 2010 | 4 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2011 | 124 | 0.090 |
Why?
|
| Phenotype | 2 | 2022 | 148 | 0.090 |
Why?
|
| Vaginal Smears | 2 | 2022 | 50 | 0.090 |
Why?
|
| Quality of Life | 3 | 2020 | 529 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2016 | 724 | 0.080 |
Why?
|
| Absorptiometry, Photon | 2 | 2016 | 52 | 0.080 |
Why?
|
| Delayed Diagnosis | 2 | 2020 | 19 | 0.080 |
Why?
|
| Systematized Nomenclature of Medicine | 1 | 2009 | 5 | 0.080 |
Why?
|
| Trans Fatty Acids | 1 | 2009 | 4 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2021 | 30 | 0.080 |
Why?
|
| Cooking | 1 | 2009 | 17 | 0.080 |
Why?
|
| Observer Variation | 1 | 2009 | 40 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 41 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 29 | 0.080 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2009 | 22 | 0.080 |
Why?
|
| Iron, Dietary | 1 | 2008 | 7 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2012 | 165 | 0.080 |
Why?
|
| Geography | 1 | 2008 | 41 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2010 | 199 | 0.080 |
Why?
|
| beta Carotene | 1 | 2008 | 17 | 0.080 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2008 | 4 | 0.080 |
Why?
|
| Vitamin E | 1 | 2008 | 20 | 0.080 |
Why?
|
| Ascorbic Acid | 1 | 2008 | 19 | 0.080 |
Why?
|
| Genetic Pleiotropy | 2 | 2020 | 9 | 0.080 |
Why?
|
| Hemochromatosis Protein | 1 | 2008 | 8 | 0.080 |
Why?
|
| Heterozygote | 1 | 2008 | 29 | 0.080 |
Why?
|
| Breast Feeding | 1 | 2010 | 133 | 0.080 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2008 | 9 | 0.080 |
Why?
|
| Antigens, Bacterial | 1 | 2007 | 8 | 0.080 |
Why?
|
| Bacterial Proteins | 1 | 2007 | 18 | 0.080 |
Why?
|
| Abortion, Therapeutic | 1 | 2007 | 2 | 0.070 |
Why?
|
| Live Birth | 1 | 2007 | 9 | 0.070 |
Why?
|
| Antibodies, Bacterial | 1 | 2007 | 38 | 0.070 |
Why?
|
| Congenital Abnormalities | 1 | 2007 | 26 | 0.070 |
Why?
|
| Infant, Low Birth Weight | 1 | 2007 | 37 | 0.070 |
Why?
|
| Genotype | 2 | 2021 | 253 | 0.070 |
Why?
|
| Thigh | 1 | 2007 | 11 | 0.070 |
Why?
|
| Waist-Hip Ratio | 1 | 2007 | 23 | 0.070 |
Why?
|
| Cesarean Section | 1 | 2007 | 30 | 0.070 |
Why?
|
| Cholesterol, HDL | 1 | 2007 | 80 | 0.070 |
Why?
|
| Peptide Hormones | 1 | 2007 | 8 | 0.070 |
Why?
|
| Papanicolaou Test | 2 | 2017 | 38 | 0.070 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 125 | 0.070 |
Why?
|
| Abortion, Spontaneous | 1 | 2007 | 52 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2007 | 157 | 0.070 |
Why?
|
| Anthropometry | 1 | 2006 | 67 | 0.070 |
Why?
|
| Sample Size | 1 | 2016 | 30 | 0.070 |
Why?
|
| Muscle Relaxation | 1 | 2006 | 3 | 0.070 |
Why?
|
| Xanthines | 1 | 2006 | 6 | 0.070 |
Why?
|
| Nitrates | 1 | 2006 | 8 | 0.070 |
Why?
|
| Genetic Markers | 2 | 2017 | 28 | 0.070 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2006 | 33 | 0.070 |
Why?
|
| Calcium Channel Blockers | 1 | 2006 | 15 | 0.070 |
Why?
|
| Europe | 2 | 2017 | 44 | 0.070 |
Why?
|
| Benzodiazepines | 1 | 2006 | 26 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 151 | 0.070 |
Why?
|
| Age Distribution | 1 | 2006 | 261 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2017 | 42 | 0.070 |
Why?
|
| African Continental Ancestry Group | 1 | 2006 | 166 | 0.070 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2006 | 85 | 0.070 |
Why?
|
| Research Design | 2 | 2010 | 402 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2015 | 23 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 20 | 0.060 |
Why?
|
| Switzerland | 1 | 2024 | 3 | 0.060 |
Why?
|
| Directories as Topic | 1 | 2003 | 1 | 0.060 |
Why?
|
| American Medical Association | 1 | 2003 | 4 | 0.060 |
Why?
|
| Residence Characteristics | 2 | 2017 | 256 | 0.060 |
Why?
|
| Whole Exome Sequencing | 1 | 2022 | 8 | 0.050 |
Why?
|
| Exome | 1 | 2022 | 25 | 0.050 |
Why?
|
| Child | 2 | 2024 | 2571 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2022 | 32 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 77 | 0.050 |
Why?
|
| Endoscopy, Digestive System | 1 | 2002 | 10 | 0.050 |
Why?
|
| Esophagitis, Peptic | 1 | 2002 | 1 | 0.050 |
Why?
|
| Hyperthermia, Induced | 1 | 2002 | 2 | 0.050 |
Why?
|
| Diabetes, Gestational | 1 | 2006 | 339 | 0.050 |
Why?
|
| Sexism | 1 | 2021 | 1 | 0.050 |
Why?
|
| Hospitals | 1 | 2022 | 80 | 0.050 |
Why?
|
| Global Health | 1 | 2001 | 33 | 0.050 |
Why?
|
| Culturally Competent Care | 1 | 2021 | 12 | 0.050 |
Why?
|
| Hormones | 1 | 2011 | 17 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2001 | 83 | 0.050 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2021 | 5 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2021 | 13 | 0.050 |
Why?
|
| Racism | 1 | 2021 | 22 | 0.050 |
Why?
|
| Dental Care | 1 | 2011 | 19 | 0.050 |
Why?
|
| Vasopressins | 1 | 2001 | 5 | 0.050 |
Why?
|
| Femur | 1 | 2020 | 10 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 5 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 6 | 0.050 |
Why?
|
| Eye Proteins | 1 | 2020 | 13 | 0.050 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 1 | 0.050 |
Why?
|
| Acute Disease | 1 | 2001 | 144 | 0.050 |
Why?
|
| Recurrence | 1 | 2001 | 187 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 6 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2020 | 69 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2019 | 3 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2019 | 7 | 0.040 |
Why?
|
| Chicago | 1 | 2019 | 27 | 0.040 |
Why?
|
| Michigan | 1 | 2019 | 26 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 26 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 17 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 4 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 8 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 45 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 674 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2019 | 29 | 0.040 |
Why?
|
| Research | 1 | 2019 | 73 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 178 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2019 | 150 | 0.040 |
Why?
|
| Vomiting | 1 | 1998 | 12 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2017 | 34 | 0.040 |
Why?
|
| North America | 1 | 2017 | 42 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 18 | 0.040 |
Why?
|
| ROC Curve | 1 | 2017 | 83 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 1997 | 20 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 46 | 0.040 |
Why?
|
| Syndrome | 1 | 1997 | 29 | 0.040 |
Why?
|
| Energy Intake | 1 | 2017 | 103 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 29 | 0.040 |
Why?
|
| Colon, Sigmoid | 1 | 2016 | 2 | 0.040 |
Why?
|
| Colon, Ascending | 1 | 2016 | 2 | 0.040 |
Why?
|
| Colon, Descending | 1 | 2016 | 2 | 0.040 |
Why?
|
| Colon, Transverse | 1 | 2016 | 2 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2016 | 26 | 0.040 |
Why?
|
| Temperature | 1 | 2016 | 18 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 34 | 0.040 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2016 | 1 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2016 | 4 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2016 | 11 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2016 | 10 | 0.030 |
Why?
|
| Seasons | 1 | 2016 | 105 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 93 | 0.030 |
Why?
|
| Cytokines | 1 | 2016 | 30 | 0.030 |
Why?
|
| Medicare Part B | 1 | 2016 | 3 | 0.030 |
Why?
|
| China | 1 | 2016 | 130 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2016 | 17 | 0.030 |
Why?
|
| Postal Service | 1 | 2016 | 83 | 0.030 |
Why?
|
| Inflammation | 1 | 2016 | 63 | 0.030 |
Why?
|
| Community Health Centers | 1 | 2017 | 112 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 2 | 0.030 |
Why?
|
| Aromatase | 1 | 2015 | 10 | 0.030 |
Why?
|
| Oxytocin | 1 | 2015 | 4 | 0.030 |
Why?
|
| Estrogen Receptor beta | 1 | 2015 | 12 | 0.030 |
Why?
|
| Cat Diseases | 1 | 2015 | 1 | 0.030 |
Why?
|
| Virus Physiological Phenomena | 1 | 2015 | 1 | 0.030 |
Why?
|
| Virus Inactivation | 1 | 2015 | 1 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 3 | 0.030 |
Why?
|
| Cats | 1 | 2015 | 8 | 0.030 |
Why?
|
| Food Contamination | 1 | 2015 | 3 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 35 | 0.030 |
Why?
|
| Foodborne Diseases | 1 | 2015 | 5 | 0.030 |
Why?
|
| Office Visits | 1 | 2016 | 86 | 0.030 |
Why?
|
| Caliciviridae Infections | 1 | 2015 | 4 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2015 | 8 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 23 | 0.030 |
Why?
|
| Plant Preparations | 1 | 2015 | 6 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 2015 | 6 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2015 | 18 | 0.030 |
Why?
|
| Food Handling | 1 | 2015 | 6 | 0.030 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2015 | 9 | 0.030 |
Why?
|
| Coffee | 1 | 2015 | 5 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2006 | 65 | 0.030 |
Why?
|
| Phylogeny | 1 | 2015 | 14 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 43 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2015 | 88 | 0.030 |
Why?
|
| Vitamins | 1 | 2015 | 65 | 0.030 |
Why?
|
| Public Health | 1 | 2015 | 82 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 270 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2014 | 44 | 0.030 |
Why?
|
| Diverticulum, Colon | 1 | 2013 | 2 | 0.030 |
Why?
|
| Twin Studies as Topic | 1 | 2013 | 3 | 0.030 |
Why?
|
| Software | 1 | 2013 | 21 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 1993 | 2 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1993 | 4 | 0.030 |
Why?
|
| Physical Examination | 1 | 2013 | 21 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2012 | 39 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2012 | 48 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2012 | 13 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2012 | 198 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2012 | 10 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 119 | 0.030 |
Why?
|
| Canada | 1 | 2011 | 67 | 0.020 |
Why?
|
| Menopause | 1 | 1992 | 72 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 247 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2010 | 28 | 0.020 |
Why?
|
| Etidronic Acid | 1 | 2009 | 3 | 0.020 |
Why?
|
| Tooth Extraction | 1 | 2009 | 5 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 1478 | 0.020 |
Why?
|
| Exercise | 1 | 2011 | 495 | 0.020 |
Why?
|
| Veterans | 1 | 2006 | 138 | 0.020 |
Why?
|
| Gastric Acidity Determination | 1 | 2002 | 1 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1993 | 1 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1993 | 2 | 0.010 |
Why?
|
| Bronchial Hyperreactivity | 1 | 1993 | 2 | 0.010 |
Why?
|
| Cell Count | 1 | 1993 | 10 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1993 | 22 | 0.010 |
Why?
|
| Pulmonary Fibrosis | 1 | 1993 | 10 | 0.010 |
Why?
|
| Pneumonia | 1 | 1993 | 56 | 0.010 |
Why?
|